MDCX · Medicus Pharma Ltd.

Medicus Pharma Ltd., a clinical-stage development company with no current revenues from drug programs, reported widening losses in Q1 FY2026 as R&D and G&A investments advanced its pipeline. Operating income deteriorated to -$8.6 million from -$5.1 million in Q1 FY2025, a -67.7% year-over-year change, primarily due to increased spending on research and development alongside general and administrative expenses. This reflects the company's R&D-stage focus, where it expects to continue incurring significant operating losses for the foreseeable future and may never become profitable.

The escalation in R&D costs stems from the start of Teverelix development, partially offset by reduced spending as SkinJect approaches the end of its Phase II trials. Management anticipates further R&D increases ahead, tied to advancing two separate Phase II trials for Teverelix. Meanwhile, G&A rose due to higher consulting fees, salaries and wages from expanded headcount at board and management levels, plus expenses for business development, investor relations, and stock-based compensation. These dynamics underscore organizational scaling to support clinical progress.

Net income deepened to -$9.0 million from -$5.1 million year-over-year (-77.2%), with diluted EPS improving to -$0.31 from -$0.42 (26.2% YoY). This per-share shift arises from the relative magnitude of losses against share count changes. Net cash provided by operating activities swung to -$9.0 million from -$3.9 million, signaling heightened cash burn to sustain operations.

Liquidity remains a key concern, as the company relies on equity sales and alternative funding without revenue generation. Management notes access to additional capital via public/private offerings, debt, collaborations, or licenses beyond recent ATM, SEPA, and debenture activities. However, without further capital, it may need cost reductions to conserve cash and meet obligations, consistent with going-concern risks in clinical-stage biopharma.